PolarityTE, Inc.

And ladies and gentlemen, please stand by. Good day and welcome to the Polarity TE first quarter 2022 business update conference call. Today's conference is being recorded. And now at this time, I would like to turn the conference over to Cameron Hoyler. Please go ahead.

Thank you, Operator. Good morning and thank you for joining Polarity TE's call to discuss first quarter 2022 results. I'm Cameron Hoyler, General Counsel. On the call today are members of the Executive Team, Chief Executive Officer and President and Jake Patterson, Chief Financial Officer. Before we begin, I would like to remind everyone that today's discussion will include statements about the company's future expectations, plans, and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. We caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors, including but not limited to those detailed under the caption risk factors that are described in our annual report on Form 10-K for the year ended December 31, 2021 and subsequent reports filed with the SEC. Any forward-looking statements made on this call speak only as of today's date, Monday, May 16, 2022. and we disclaim any obligation to update such statements to reflect events or circumstances that occur after today's call, except as required by law. I'd like to highlight to participants that the call is being recorded. A replay of the recorded call will be available on our website in the Investor Relations section shortly following the conclusion of the call. Additionally, it is the property of Polarity TE, and any redistribution, retransmission, or rebroadcast of the call in any form without Polarity TE's express written consent is strictly prohibited. I would now like to turn the call over to Richard Hague, CEO.

Thanks, Cameron, and good morning and welcome, everyone. As we announced via a press release on Friday, I'm very pleased to report that the FDA has granted SkinTE a Regenerative Medicine Advanced Therapy designation. This RMAT designation is an incredible accomplishment for our company and comes on the heels of the first patient being enrolled in our Phase III Pivotal Study of SkinTE and Wagner2 diabetic foot ulcers less than a month ago. I'll elaborate on the importance of the RMAT and the status of our ongoing pivotal trial after we discuss the quarter's financials. But needless to say, we are thrilled with the progress that we've made over the last several months. I would now like to turn the call over to Jake Patterson, our CFO.